Our vision

GL Pharma was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and has a history of more than 70 years.

We develop, produce and market unique brand name products as well as off-patent products for the wellbeing of people in Austria and abroad. As a supplier to the healthcare sector, we partner with general practitioners, pharmacists, their patients and pharmaceutical wholesalers. As an international player, we market our products through our licensees and branch offices in more than 50 countries.

Our core competence concentrates on three different business areas:

  • Cardiovascular system
  • Central nervous system
  • Urology, oncology and opioid substitution therapy

Management team

Martin Bartenstein

CEO

 

Ilse Bartenstein

CEO

 

Our history

1947/48

Foundation of Lannacher Heilmittel in Lannach/Graz and Gerot Pharmazeutika in Vienna

1966

Bartenstein family takes over Lannacher Heilmittel

1997

Acquisition of Gerot Pharmazeutika by Lannacher Heilmittel

2003

Start of operation in the state-of-the-art solid forms production site Lannach/Graz

2009

Lannacher and Gerot merge under the brand G.L. Pharma

2012

Strategic cooperation with Bausch Health in Russia and CIS markets

Company

Facts & Figures

Markets

Our products can be found in more than 50 markets worldwide. GL Pharma has 16 distribution structures in Europe and a subsidiary in Central America.

Headcount

~1.100 employees

Revenues

247 MEUR (2022), 363 MEUR group revenue including Genericon Pharma

Production Volume

Around 4.670 M defined daily doses

Transparency

In healthcare, trust is required.

GL Pharma works closely with physicians, other healthcare professionals and medical facilities to provide an optimum patient care.
As a responsible company, GL Pharma is committed to transparency.

Within the EFPIA Transparency Code, we disclose financial contributions to healthcare professionals.